Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine

NCT06603558 · clinicaltrials.gov ↗

RECRUITING

Status

3000

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Migraine
Episodic Migraine
Migraine

Interventions

DRUG: Atogepant

Sponsor

AbbVie